NewAmsterdam Pharma Company N.V.
Symbol: NAMS
NASDAQ
21.86
USDTržní cena dnes
87.5675
Poměr P/E
0.0000
Poměr PEG
1.95B
MRK Cap
- 0.00%
Výnos DIV
NewAmsterdam Pharma Company N.V. (NAMS) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 340.4 | 438.5 | 53.1 | ||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.net-receivables | 0 | 1.9 | 1.9 | 4.3 | ||||
balance-sheet.row.inventory | 0 | -1.9 | 0 | 0 | ||||
balance-sheet.row.other-current-assets | 0 | 6.3 | 7.6 | 1.5 | ||||
balance-sheet.row.total-current-assets | 0 | 346.8 | 448.1 | 58.9 | ||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.goodwill | 0 | 0 | 0.2 | 0 | ||||
balance-sheet.row.intangible-assets | 0 | 0.2 | 82.9 | 0 | ||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.2 | 83.2 | 0 | ||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0.1 | 0 | ||||
balance-sheet.row.total-non-current-assets | 0 | 0.3 | 83.5 | 0.9 | ||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-assets | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.account-payables | 0 | 16.9 | 11.1 | 6.2 | ||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | ||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 2.8 | ||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0.1 | 0.1 | ||||
Deferred Revenue Non Current | 0 | 1 | 4.5 | 0 | ||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||
balance-sheet.row.other-current-liab | 0 | 24 | 11.3 | 0 | ||||
balance-sheet.row.total-non-current-liabilities | 0 | 8.8 | 11.6 | 0.1 | ||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.total-liab | 0 | 58.7 | 47.1 | 10 | ||||
balance-sheet.row.preferred-stock | 0 | 317 | 0 | 0 | ||||
balance-sheet.row.common-stock | 0 | 10.2 | 599.2 | 83.9 | ||||
balance-sheet.row.retained-earnings | 0 | -317 | -119.4 | -34.7 | ||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 4.4 | 4.7 | 0.6 | ||||
balance-sheet.row.other-total-stockholders-equity | 0 | 273.8 | 0 | 0 | ||||
balance-sheet.row.total-stockholders-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||
Total Investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.net-debt | 0 | -340.4 | -438.4 | -52.9 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -176.9 | -78.1 | -28.6 | ||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.1 | 0 | ||||
cash-flows.row.deferred-income-tax | 0 | 5.2 | 0 | -1.4 | ||||
cash-flows.row.stock-based-compensation | 0 | 24.6 | 3.9 | 1 | ||||
cash-flows.row.change-in-working-capital | 0 | 5.9 | 11.5 | 3.8 | ||||
cash-flows.row.account-receivables | 0 | 3.7 | -3.9 | -4.6 | ||||
cash-flows.row.inventory | 0 | -3.7 | 5.9 | -0.1 | ||||
cash-flows.row.account-payables | 0 | 5.1 | -2 | 8.6 | ||||
cash-flows.row.other-working-capital | 0 | 0.8 | 11.5 | 0 | ||||
cash-flows.row.other-non-cash-items | 0 | 0 | 70.6 | 0 | ||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | ||||
cash-flows.row.common-stock-issued | 0 | 8.1 | 377.8 | 69 | ||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-financing-activites | 0 | 0.8 | -2.5 | 0 | ||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 8.9 | 375.2 | 69 | ||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5.1 | 1.6 | 1.4 | ||||
cash-flows.row.net-change-in-cash | 0 | -127.3 | 385.4 | 45.2 | ||||
cash-flows.row.cash-at-end-of-period | 0 | 340.4 | 438.5 | 53.1 | ||||
cash-flows.row.cash-at-beginning-of-period | 0 | 467.7 | 53.1 | 7.9 | ||||
cash-flows.row.operating-cash-flow | 0 | -141.2 | 8 | -25.2 | ||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||
cash-flows.row.free-cash-flow | 0 | -141.2 | 8 | -25.2 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 14.1 | 97.5 | 0 | ||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.gross-profit | 0 | 14 | 97.4 | 0 | ||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.research-development | 0 | - | - | - | ||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.other-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.operating-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.cost-and-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.interest-income | 0 | 11.3 | 0 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.total-other-income-expensenet | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.total-operating-expenses | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 60.7 | 0 | ||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||
income-statement-row.row.operating-income | 0 | -183 | -67.6 | -29.8 | ||||
income-statement-row.row.income-before-tax | 0 | -176.9 | -78.1 | -28.6 | ||||
income-statement-row.row.income-tax-expense | 0 | 0 | 70.8 | 0.2 | ||||
income-statement-row.row.net-income | 0 | -176.9 | -148.9 | -28.8 |
Často kladené otázky
Co je NewAmsterdam Pharma Company N.V. (NAMS) celková aktiva?
NewAmsterdam Pharma Company N.V. (NAMS) celková aktiva jsou 347097000.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 1.000.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -0.345.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.206.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou -0.335.
Co je NewAmsterdam Pharma Company N.V. (NAMS) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je -176937000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 60000.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 189195000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.